Biodexa Pharmaceuticals is a UK pharmaceutical company developing a pipeline of products aimed at rare and orphan diseases, mainly in the area of oncology. Its main program focuses on primary and metastatic cancers of the brain and central nervous system.


The company has developed an experimental drug, known as MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma (rGBM), diffuse midline glioma (DMG) (also known as diffuse intrinsic pontine glioma (DIPG)) and medulloblastoma. 


The reSOLVE clinical trials program is Biodexa’s commitment to resolving unmet medical needs. This is part of our company’s Mission to advance medicines that will provide a brighter future for patients with serious conditions; especially those not fully served by existing treatments. The name "reSOLVE" was inspired by both our Mission, and our MidaSolve™ technology platform. This platform is used to produce solubilized formulations of poorly water-soluble substances, therefore enabling a direct delivery to the site of action. MTX110 was the first product we produced using the MidaSolve™ platform.


MTX110 is a liquid form of a drug known as Panobinostat. Biodexa Pharmaceuticals is using this liquid form to deliver the product directly to the site of the tumor, either in the brain or spinal column. This website provides information about the studies being conducted using MTX110.

About the reSOLVE Clinical Trials

Clinical Trial Patient with Glioblastoma

Please select the Clinical Trial/indication for more information.


Recurrent Glioblastoma


MAGIC-G1

Open in 2023

The MAGIC-G1 trial is a phase I trial investigating the safety of MTX110 in patients diagnosed with recurrent glioblastoma (rGBM). In the MAGIC-G1 clinical trial, MTX110 is administered directly to the site of the tumor using a technique called convection-enhanced delivery (CED). The trial is being conducted in two US hospitals.

Current Status: Recruiting

Medulloblastoma


MTX110-101

Open in 2023

Conducted at the McGovern Medical School/UTHeath and Children’s Memorial Hermann Hospital in Houston, the MTX110-101 Clinical Trial is a phase I trial investigating the safety of MTX110 in children and adults suffering with medulloblastoma.

Current Status: Recruiting

This website is intended for residents of the USA only. This site does not provide medical advice. The site, content, and services do not provide any form of medical advice or recommendations and is provided for general information purposes only. For full disclaimer, please refer to the terms and conditions of use.
biodexa pharmaceuticals logo
biodexa pharmaceuticals logo
Biodexa Limited, is a subsidiary of Biodexa Pharmaceuticals PLC
Share by: